Gaudet, Daniel

Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial

Gouni-Berthold, I., Alexander, V., Digenio, A., DuFour, R., Steinhagen-Thiessen, E., Martin, S., Moriarty, P., Hughes, S., Jones, R., Witztum, J. L., et al. (2017) · Atherosclerosis Supplements

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 21

Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management

Brown, W. V., Goldberg, I., Duell, B., & Gaudet, D. (2018) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 21

Natural History (up to 15 years) of Platelet Count in 84 Patients with Familial Hyperchylomicronemia Due to Lipoprotein Lipase Deficiency

Gaudet, D., Baass, A., Tremblay, K., Brisson, D., Laflamme, N., Paquette, M., Dufour, R., & Bergeron, J. (2017) · Journal of Clinical Lipidology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 19

Roundtable on etiology of familial chylomicronemia syndrome

Brown, W. V., Gaudet, D., Goldberg, I., & Hegele, R. (2018) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 18

Effect of obesity on HDL and LDL particle sizes in carriers of the null P207L or defective D9N mutation in the lipoprotein lipase gene: the Québec LipD Study

Ruel, I. L., Gaudet, D., Perron, P., Bergeron, J., Julien, P., & Lamarche, B. (2003) · International Journal of Obesity

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 18

Abstract 17120: ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 study results

Watts, G. F., Gaudet, D., ALTAMIRANO, D., Hegele, R., Ballantyne, C. M., Nicholls, S., Chang, T., Alagarsamy, S., Fu, R., San Martin, J., et al. (2023) · Circulation

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 9

Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates robust and durable TG reductions in patients with mixed dyslipidemia, MUIR final results

Vasas, S., Azizad, M., Clifton, P., Rosenson, R., Gaudet, D., Hellawell, J., Chang, T., Melquist, S., Fu, R., Mushin, M., et al. (2024) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 3